Get the Stockscreener App
2.2704
3.67%
0.0804
iBio Inc stock is traded at $2.2704, with a volume of 97,530.
It is up +3.67% in the last 24 hours and down -26.52% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.19
Open:
$2.19
24h Volume:
97,530
Relative Volume:
0.81
Market Cap:
$20.74M
Revenue:
$2.05M
Net Income/Loss:
$-27.28M
P/E Ratio:
-0.3942
EPS:
-5.76
Net Cash Flow:
$-18.89M
1W Performance:
+5.60%
1M Performance:
-26.52%
6M Performance:
-2.56%
1Y Performance:
+751.61%
1-Day Range:
$2.19
$2.34
1-Week Range:
$2.0646
$2.3918
52-Week Range:
$0.20
$4.98
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IBIO | 2.2601 | 20.74M | 2.05M | -27.28M | -18.89M | -5.76 |
| VRTX | 448.24 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.59 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.88 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.69 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.83 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
iBio Inc. stock rises Friday, outperforms market - MarketWatch
Ikarian Capital, LLC Adjusts Stake in iBio Inc - GuruFocus.com
ADAR1 Capital Management's Strategic Acquisition in iBio Inc - GuruFocus.com
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio Inc Reports Fiscal Q1 GAAP EPS of -$0.52, Missing Estimates; No Revenue Reported, Aligning with Expectations - GuruFocus.com
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
iBio Reports Fiscal First Quarter 2025 Financial Results - GlobeNewswire
iBio (NYSE:IBIO) Trading Down 0.6% – Here’s What Happened - Defense World
iBio Inc. stock remains steady Monday, underperforms market - MarketWatch
iBio Inc. stock rises Monday, outperforms market - MarketWatch
iBio Unveils AI-Driven Antibody Discovery Strategy - TipRanks
Plant-Based Vaccines Market Is Booming Worldwide 2024-2031 | - openPR
iBio Inc. stock remains steady Thursday, underperforms market - MarketWatch
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments - GlobeNewswire Inc.
Lead molecule identified under Ibio and Astralbio’s myostatin program for obesity - BioWorld Online
Items Tagged with 'Astralbio Inc.' - BioWorld Online
iBio and AstralBio Provide Update on Myostatin Program for Obesity - GlobeNewswire
IBio, Inc. and AstralBio Provide Update on Myostatin Program for Obesity - Marketscreener.com
IBIO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
What is going on with iBio Inc? Sentiment Analysis - US Post News
iBio Inc. stock falls Friday, underperforms market - MarketWatch
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio (NYSE:IBIO) Trading 1.6% Higher - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Biafra: Why We Ended Nnamdi Kanu’s Trial – Lawyer Ejimakor - Tori.ng
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IOVA’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):